LINE1 CpG site | # events/# patients* | Extent methylation†| HR‡ | 95% CI; P value | HRcont.§ | 95% CI; P value |
---|
CpG1
| 13/21 | <25.68 | 1** | Â | 1.51 | 1.06-2.16; 0.02 |
 | 17/21 | ≥25.68 | 1.57 | 0.76-3.24; 0.22 |  |  |
CpG2
| 12/21 | <27.26 | 1 | Â | 1.60 | 1.02-2.52; 0.04 |
 | 18/21 | ≥27.26 | 2.12 | 1.01-4.44; 0.04 |  |  |
CpG3
| 11/21 | <40.46 | 1 | Â | 1.49 | 1.06-2.09; 0.02 |
 | 19/21 | ≥40.46 | 2.63 | 1.21-5.69;. 0.01 |  |  |
- * number of patients who died (# events) and total number of patients in the group (# patients) are reported;
- †Patients were divided according to the % of methylation of the specified CpG site being <or ≥ the median % methylation measured in the examined patients' population;
- ‡ Cox proportional hazard method was used to examine the effect of LINE-1 methylation on OS. Results were presented as Hazard Ratios (HR) with corresponding 95% Confidence Intervals (CI);
- § LINE-1 methylation was also evaluated as continuous variable. The HR value is that of the LINE-1 methylation relative to an increase of 10%;
- ** set as reference.